AZ expanding Maryland biologics center; Valeant eyes securities buyback;

@FiercePharma: #FDA approves Purdue's abuse-resistant Hysingla, a hydrocodone pill aimed at knocking off Zohydro. Story | Follow @FiercePharma

@CarlyHFierce: #ICYMI yesterday - Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results. | Follow @CarlyHFierce

> AstraZeneca ($AZN) is socking $200 million-plus into expansions at its Frederick, MD biologics manufacturing center. Release

>Valeant Pharmaceuticals ($VRX) says it could buy back up to $2 billion worth of securities just days after losing a bid to acquire Allergan. Report

> The Washington Post calls Pfizer's ($PFE) failed bid for AstraZeneca the year's "biggest financial turkey." More

Medical Device News

@FierceMedDev: InfoBionic gets $17M to offer cloud-based cardiac monitoring. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. See my updated story. | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off $SNN. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article | Follow @EmilyWFierce

> Gates Foundation backs Ebola trials for plasma-based and other treatments. Article

> Tandem partners for open-source software to improve insulin pump data access. More

> Boston Scientific ordered to hand over $18.5M in vaginal mesh litigation. Story

Biotech News

@FierceBiotech: EuroBiotech Report: U.K. starts ambitious drug dev review, Onxeo to raise €41.6M, Galapagos mulls Nasdaq listing. More | Follow @FierceBiotech

@JohnCFierce: 5 of the top 10 biotech news stories of the year so far in FierceBiotech are on immuno-oncology. Oh, my. | Follow @JohnCFierce

@DamianFierce: $ABBV's hep C combo will be branded as Viekirax + Exviera (at least in Europe). More from the EMA | Follow @DamianFierce

> Beware sketchy biotechs with big plans for Ebola, SEC says. Article

> AbbVie gets an EU green light for its next-gen hep C treatment. More

> Purdue wins a pain pill approval with Zohydro in its crosshairs. News

And Finally... Bloomberg takes a look at the code names used during the Valeant-Allergan ($AGN)-Actavis ($ACT) takeover battle, including Valeant's "Project Olympus" and Actavis' "Project Fruit Basket." More

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.